Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Tamas, Maria-Magdalena (36817118000)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    "To be or not to be," ten years after: Evidence for mixed connective tissue disease as a distinct entity
    (2012)
    Cappelli, Susanna (36096543700)
    ;
    Bellando Randone, Silvia (35218795900)
    ;
    Martinović, Dušanka (16417426000)
    ;
    Tamas, Maria-Magdalena (36817118000)
    ;
    Pasalić, Katarina (51864514400)
    ;
    Allanore, Yannick (7003519327)
    ;
    Mosca, Marta (7006720974)
    ;
    Talarico, Rosaria (24330409200)
    ;
    Opris, Daniela (15756184400)
    ;
    Kiss, Csaba G. (18340304000)
    ;
    Tausche, Anne-Kathrin (55915616000)
    ;
    Cardarelli, Silvia (57226555478)
    ;
    Riccieri, Valeria (7003568453)
    ;
    Koneva, Olga (6508032421)
    ;
    Cuomo, Giovanna (58021681500)
    ;
    Becker, Mike Oliver (57199798838)
    ;
    Sulli, Alberto (7003533074)
    ;
    Guiducci, Serena (6701771669)
    ;
    Radić, Mislav (56277745800)
    ;
    Bombardieri, Stefano (7006270830)
    ;
    Aringer, Martin (7003332848)
    ;
    Cozzi, Franco (35271801400)
    ;
    Valesini, Guido (7005133584)
    ;
    Ananyeva, Lidia (6603356433)
    ;
    Valentini, Gabriele (7102929864)
    ;
    Riemekasten, Gabriela (57203073213)
    ;
    Cutolo, Maurizio (7103329735)
    ;
    Ionescu, Ruxandra (36196636800)
    ;
    Czirják, László (7004435091)
    ;
    Damjanov, Nemanja (8503557800)
    ;
    Rednic, Simona (16417734900)
    ;
    Matucci Cerinic, Marco (7005642558)
    Objectives: To determine if mixed connective tissue disease (MCTD) can be considered an independent clinical entity, to compare 3 different classification criteria for MCTD (Kasukawa, Alarcón-Segovia, and Sharp), and to define predictors (clinical features and autoantibodies) of potential evolution toward other connective tissue diseases (CTDs). Methods: One hundred sixty-one MCTD patients were evaluated retrospectively at the diagnosis and in 2008. They were classified, at the diagnosis, according to the 3 classification criteria of MCTD (Sharp, Alarcón-Segovia, and Kasukawa) and reclassified in 2008 according to their evolution. Statistical analyses were performed to find out predictors (clinical features and autoantibodies) of evolution into other CTDs. Results: After a mean of 7.9 years of disease, 57.9% of patients still satisfied MCTD classification criteria of Kasukawa; 17.3% evolved into systemic sclerosis, 9.1% into systemic lupus erythematosus, 2.5% into rheumatoid arthritis, 11.5% was reclassified as affected by undifferentiated connective tissue disease, and 1.7% as suffering from overlap syndrome. Kasukawa's criteria were more sensitive (75%) in comparison to those of Alarcón-Segovia (73%) and Sharp (42%). The presence of anti-DNA antibodies (P = 0.012) was associated with evolution into systemic lupus erythematosus; hypomotility or dilation of esophagus (P < 0.001); and sclerodactyly (P = 0.034) with evolution into systemic sclerosis. Conclusions: MCTD is a distinct clinical entity but it is evident that a subgroup of patients may evolve into another CTD during disease progression. Initial clinical features and autoantibodies can be useful to predict disease evolution. © 2012 Elsevier Inc.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback